New analysis bolsters metformin as first line in type 2 diabetes
Patients with type 2 diabetes treated with metformin as a monotherapy are at a decreased risk for cardiovascular mortality when compared with those on sulfonylurea monotherapy, according to a report...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Metformin